RxDoctor Payments Data

David Bragin-Sanchez, MD

Advanced Heart Failure and Transplant Cardiology · Spokane, WANPI 1457364770

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,023 of the $83,036 with a category attached, or 85.5%. Johnson & Johnson accounts for 64.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $41,485 and has fallen 62.7% since, to $15,469 in 2025. Among advanced heart failure and transplant cardiology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$83,036in general payments, 2019–2025

Across 242 payments — averaging $343.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$53K
  • Bridgebio Pharma, Inc.$15K
  • Novartis$10K
  • Abbott$2K
  • Actelion Pharmaceuticals US, Inc.$750
  • AstraZeneca$533
  • plus $572 from 10 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$71,02386%
  • Travel & lodging$6,0907%
  • Food & beverage$5,2246%
  • Education$3990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,036 in reported general payments places this provider in the 90th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

See all advanced heart failure and transplant cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$152,812
Medicare patients
718
Services billed
1,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis95$2,478,351
OpsumitMacitentan49$621,292
EntrestoSacubitril/Valsartan281$371,120
VyndaqelTafamidis Meglumine13$295,058
EliquisApixaban199$239,934
FarxigaDapagliflozin Propanediol199$206,220
JardianceEmpagliflozin157$170,597
AdempasRiociguat11$151,997
XareltoRivaroxaban116$131,183
Tadalafil37$21,588
Eplerenone140$14,640
Metoprolol Succinate404$6,450
Torsemide198$3,898
Candesartan Cilexetil94$3,879
VascepaIcosapent Ethyl12$3,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$81$3,013,343307 claims
Actelion Pharmaceuticals US, Inc.Opsumit$750$621,29249 claims
NovartisEntresto$10,370$371,120281 claims
AstraZenecaFarxiga$533$206,220199 claims
Boehringer IngelheimJardiance$127$170,597157 claims
BayerAdempas$16$151,99711 claims
Johnson & JohnsonXarelto$53,494$131,183116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

Other advanced heart failure and transplant cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →